Digital Therapeutic Program for Interstitial Lung Disease Adherence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for interstitial lung disease (ILD), particularly idiopathic pulmonary fibrosis (IPF), lack effective solutions for managing both physical symptoms and associated anxiety, leading to poor quality of life and limited treatment adherence due to side effects and accessibility issues with traditional cognitive behavioral therapy (CBT).
Innovation Solution
A combination of pharmaceutical treatments, such as antifibrotic agents and anxiolytic drugs, is administered alongside a digital therapeutic program delivering cognitive behavioral therapy (CBT) tailored to address anxiety and behavioral restrictions, improving adherence and quality of life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional cognitive behavioral therapy (CBT) is used to treat anxiety in ILD patients, then psychological support is provided, but accessibility and adherence are limited due to availability and side effect concerns
Solution Approach 1:
The patent creates a digital copy of traditional CBT therapy through a therapeutic program delivered via processor-based devices. The program replicates cognitive behavioral therapy techniques in a digital format that can be accessed remotely, eliminating geographical and availability barriers while maintaining therapeutic effectiveness. This digital copying enables patients to access CBT without visiting physical therapy locations, directly improving accessibility while ensuring consistent delivery of the therapy protocol.
2Reliability
If pharmaceutical treatments are administered to ILD patients, then physical symptoms are managed, but anxiety and quality of life are not adequately addressed
Solution Approach 1:
The patent merges pharmaceutical treatment with digital cognitive behavioral therapy into a single integrated treatment protocol. The processor-based device delivers therapeutic programs that run concurrently with medication administration, combining physical symptom management with psychological support. This merging ensures patients receive both pharmacological intervention for ILD symptoms and CBT for anxiety, creating a comprehensive treatment approach that addresses multiple aspects of the disease without requiring separate treatment schedules.
Solution Approach 2:
The therapeutic program delivered by the processor-based device serves multiple functions: it provides cognitive behavioral therapy for anxiety, monitors treatment adherence, and supports overall mental health management. This multi-functional approach allows a single digital intervention to address various psychological needs simultaneously, making the treatment system versatile enough to handle both anxiety management and treatment compliance without adding complexity to the patient's routine.
3Ease of operation
If digital therapeutic programs are used to deliver CBT, then accessibility and adherence improve, but integration with pharmaceutical treatment requires coordination
Solution Approach 1:
The processor-based device acts as an intermediary that coordinates between pharmaceutical treatment and digital CBT delivery. The device manages the integration by scheduling and delivering therapeutic programs that complement medication administration, tracking adherence to both treatment modalities, and providing a unified interface for patients. This intermediary function simplifies the coordination complexity by centralizing the management of both treatment aspects within a single digital platform, reducing the burden on patients to manually coordinate separate treatments.
Data Source
AI summary
Aspects of the present disclosure are directed to methods of treating a patient diagnosed with an interstitial lung disease (ILD), comprising administering a pharmaceutical drug for treating the ILD in a treatment regimen effective to treat fibrosis, inflammation, and/or vasculopathy, and in conjunction with the administration of the pharmaceutical drug, engaging in a self-directed digital therapeutic program that treats patient anxiety relating to the administration of the pharmaceutical drug, wherein the engaging in the self-directed digital therapeutic program is effective to increase adherence to the treatment regimen. Suitable pharmaceutical treatments include those that are useful in the therapy of an ILD, including pharmaceutical treatments that are in some way disease-modifying and/or capable of altering the course or the pathology of the ILD or at least slowing its progression, such as such as an antifibrotic agent, an immunomodulatory imide drug (IMID) or an angiotensin II type 2 receptor agonist (ATRAG).